Search

Temocapril

Temocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States, but is approved in Japan and South Korea.

Ferrous asparto glycinate

Ferrous asparto glycinate is an iron-amino acid chelate. It is available as a dietary supplement used in the treatment of iron deficiency and iron deficiency anemia.

Urethane

Urethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.

Glycol salicylate

It is found as an active ingredient and topical analgesic in patches used to provide relief for mild to moderate muscle and joint pain [L2686]. … Glycol salicylate, also known as _2-hydroxyethyl salicylate_, is a benzoate ester formed from the condensation of the carboxy group of salicylic acid with one of the hydroxy groups of ethylene glycol.

Tea tree oil

It may be referred to as _Melaleuca alternifolia_ oil. … It has been a popular ingredient in a variety of household and cosmetic products due to its antiseptic, anti-inflammatory, broad-spectrum antimicrobial and antioxidant properties [A32438].

Eplontersen

[A262985] As eplontersen targets both the WT and mutant TTR, it poses tremendous promises as a treatment. … It was previously investigated as a potential treatment for hereditary transthyretin-mediated amyloidosis.

Methoxyamine

Tavaborole

Tavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to *Trichophyton rubrum* or *Trichophyton mentagrophytes … Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).

Econazole

A broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.

Vayarin

A slow response time of 12 weeks is an impediment to successful management of ADHD as only 41.6% of subjects prescribed Vayarin remained compliant for the duration of the study. … Vayarin is a novel therapy for ADHD that appears to be effective in several studies [L1501, L1502, L1503].